Pulmonary Hypertension in Patients With Myeloproliferative Neoplasms

Odense University Hospital180 enrolled

Overview

This is an observational prospective study aiming to clarify the prevalence of pulmonary hypertension in patients with Myeloproliferative Neoplasms and their prognosis. All patients attending our department with the above mentioned neoplasms will be offered inclusion in this study. All will have an echo performed and patients identified as being at risk of pulmonary hypertension will be offered complete investigation as specified by the European Cardiology Association. All patients will be followed up for a total of five years to identify prognosis.

Study Type

OBSERVATIONAL

Enrollment

180

Conditions

Myeloproliferative Disorders Pulmonary Hypertension

Interventions

RadiologyRADIATION

Only a small subsample will require CT and right heart catherisation

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Myeloproliferative Neoplasms (PV, ET, PMF according to WHO classification) Exclusion Criteria: * Pregnancy * Lack of informed consent * Age \< 18 years * Cognitive dysfunctions

Locations (1)

Odense University Hospital

Odense, Denmark

Outcomes

Primary Outcomes

Prevalence of pulmonary hypertension at initial presentation and first echo

Time frame: Initial recruitment

Secondary Outcomes

Mortality

Time frame: 1 and 5 years

Incidence of pulmonary hypertension while under follow-up

Time frame: 5 years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.